| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:12209177 | IVR | 3750 mg/L | 3750 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations |
| IVR | 300 mg/L | 300 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 1000 mg/L | 1000 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 5000 mg/L | 5000 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 1250 mg/L | 1250 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 7500 mg/L | 7500 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 10000 mg/L | 10000 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 10000 mg/L | 10000 mg/L | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 15000 mg/L | 15000 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 15000 mg/L | 15000 mg/L | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 20000 mg/L | 20000 mg/L | Increased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 30000 mg/L | 30000 mg/L | Increased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 30000 mg/L | 30000 mg/L | Increased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 30000 mg/L | 30000 mg/L | Changes in haemocrit values | Immunological endocrine-mediated perturbations | |
| IVR | 30000 mg/L | 30000 mg/L | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 30000 mg/L | 30000 mg/L | Atrophy of mammary gland | Reproductive endocrine-mediated perturbations | |
| IVR | 30000 mg/L | 30000 mg/L | Uterine atrophy | Reproductive endocrine-mediated perturbations | |
| IVR | 30000 mg/L | 30000 mg/L | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 30000 mg/L | 30000 mg/L | Increased brain weights | Neurological endocrine-mediated perturbations | |
| IVR | 30000 mg/L | 30000 mg/L | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 2500 mg/L | 2500 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 625 mg/L | - | No significant effects observed | - | |
| IVR | 1880 mg/L | - | No significant effects observed | - | |
| IVR | 3000 mg/L | 3000 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 3000 mg/L | 3000 mg/L | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.